Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(165 produtos)
- Bcr-Abl(117 produtos)
- EGFR(562 produtos)
- FAK(72 produtos)
- FLT(89 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(177 produtos)
- JAK(245 produtos)
- PDGFR(127 produtos)
- RAAS(86 produtos)
- Src(82 produtos)
- Syk(37 produtos)
- Trombina(52 produtos)
- VDA(2 produtos)
- VEGFR(239 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2243 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MM-589
CAS:MM-589 is a potent WD repeat domain 5 (WDR5) inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.Fórmula:C28H44N8O5Pureza:98%Cor e Forma:SolidPeso molecular:572.70Lomonitinib
CAS:Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor with antitumor properties. It shows promise for research in myeloid leukemia.
Fórmula:C27H24N4O2Cor e Forma:SolidPeso molecular:436.505EGFR-IN-146
CAS:EGFR-IN-146 is an EGFR inhibitor that suppresses the EGFR signaling pathway and improves insulin sensitivity by activating the AMPK pathway. It effectively reduces blood glucose levels and body weight, showing great potential in the study of diabetes and obesity.Fórmula:C20H16N4Cor e Forma:SolidPeso molecular:312.368MTX-216
CAS:MTX-216 is an ATP-competitive inhibitor targeting both PI3K and EGFR. It simultaneously inhibits Ki-67 and ribosomal S6 phosphorylation, inducing apoptosis in NF1LOF cells. Additionally, MTX-216 suppresses SYK kinase activity with an IC50 of 281 nM. This compound is applicable for melanoma research.Fórmula:C22H14Cl2FN5O2SCor e Forma:SolidPeso molecular:502.348BMS-986143
CAS:BMS-986143: oral BTK inhibitor, IC50=0.26 nM, potential for autoimmune research, also targets TEC, BLK, BMX, TXK, YES1, ITK.Fórmula:C31H24Cl2N4O4Cor e Forma:SolidPeso molecular:587.45JAK3/BTK-IN-4
CAS:JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)Fórmula:C21H25ClN8OCor e Forma:SolidPeso molecular:440.93FLT3-IN-13
FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.Fórmula:C20H14N4O2Cor e Forma:SolidPeso molecular:342.35FLT3/ITD-IN-1
FLT3/ITD-IN-1 inhibits FLT3-ITD with IC50s: 38.2 nM (FLT3) and 144.1 nM (ITD), and fights acute myeloid leukemia.Fórmula:C19H22N6O2Cor e Forma:SolidPeso molecular:366.42FGFR4-IN-4
CAS:FGFR4-IN-4 is a FGFR4 inhibitor with anti-tumor activity.Fórmula:C28H32Cl2N6O5Pureza:98%Cor e Forma:SolidPeso molecular:603.5HER2-IN-9
HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.Fórmula:C19H14BrF3N2OCor e Forma:SolidPeso molecular:423.23BML-265
CAS:BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.Fórmula:C18H15N3O2Cor e Forma:SolidPeso molecular:305.331VEGFR-2-IN-11
VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.Fórmula:C29H22BrN5SCor e Forma:SolidPeso molecular:552.49ERBB agonist-1
CAS:ERBB agonist-1, ERBB4 agonist (EC50=10.5 μM), induces receptor dimerization/phosphorylation of Akt and ERK1/2, cardioprotective.Fórmula:C24H25N3O2SPureza:99.90%Cor e Forma:SolidPeso molecular:419.54Ref: TM-T204401
1mgA consultar5mgA consultar10mg124,00€25mg241,00€50mg358,00€100mgA consultar1mL*10mM (DMSO)94,00€FAK-IN-26
CAS:FAK-IN-26 is a blood-brain barrier-penetrating inhibitor of Focal Adhesion Kinase (FAK) with an IC50 of 0.87 nM. It significantly reduces tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 exhibits potent anticancer activity, achieving tumor inhibition rates of 59.15% and 57.9% in A549 and SKOV-3 tumor mouse models, respectively.
Fórmula:C20H19BrFN5O2Cor e Forma:SolidPeso molecular:460.30(-)-Cevimeline hydrochloride hemihydrate
(-)-Cevimeline HCl hemihydrate, a muscarinic agonist, treats Sjogren's xerostomia. Quick absorption, species-dependent metabolism.Fórmula:C10H19ClNO1·5SPureza:98%Cor e Forma:SolidPeso molecular:244.78Tyk2-IN-3
CAS:Tyk2-IN-3 is an inhibitor of Tyk2 pseudokinase (IC50: 485 nM).Fórmula:C25H24N6O3S2Pureza:98%Cor e Forma:SolidPeso molecular:520.63(Rac)-PT2399
CAS:(Rac)-PT2399 is a potent and specific inhibitor of hypoxia-inducible factor 2a (HIF-2α)(IC50 of 0.01 μM).Fórmula:C17H10F5NO4SCor e Forma:SolidPeso molecular:419.32VEGFR-2-IN-26
CAS:VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.Fórmula:C24H19F3N6O2Cor e Forma:SolidPeso molecular:480.44JAK-IN-19
JAK-IN-19 inhibits JAK (pIC50: 7.2, 7.7), less so for VEGFR2 (7.0) and Aurora B (5.8).Fórmula:C26H36FN5O2Cor e Forma:SolidPeso molecular:469.59EGFR/HER2-IN-5
EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.Cor e Forma:Solid
